{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:52:02Z","timestamp":1789487522345,"version":"build-2803163510"},"reference-count":200,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite a myriad of medicinal breakthroughs in lipid-lowering and antithrombotic therapies, cardiovascular diseases (CVDs) are still the main killers worldwide. According to the consolidated scientific evidence, atherosclerosis, ischemic heart disease, and other vascular pathologies are attributed to endothelial dysfunction and vascular inflammation. The standard treatments\u2019 failure to adequately control the inflammatory and endothelial pathways has led researchers to biologics that are molecularly specific. Nanobodies (Nbs) are single-domain antibody fragments obtained from camelid heavy-chain antibodies. Due to their small size, good tissue penetration, and stability, they are regarded as therapeutic agents and diagnostic tools. This paper is focused on the current and potential future uses of nanobodies in the treatment of endothelial activation, the blockade of adhesion molecule expression, and the management of cytokine-induced vascular inflammation. The literature shows that diagnostic nanobody tracers achieve high accuracy for vascular inflammation imaging, yet therapeutic Nbs exist only in preclinical stages. PANX1-blocking Nbs show promise for treating ischemia\u2013reperfusion injury, and IL-1\u03b2-targeted Nbs demonstrate effectiveness in reducing hypoxia-induced damage to endothelial cells. The therapeutic potential of Nbs has been proven by caplacizumab, which functions as an anti-vWF nanobody, but its approved medical use exists only for hematologic disorders. The therapeutic potential of Nbs remains unexplored for ROS, ox-LDL, AT1R, and chemokines CCL2 and CCL5 because researchers have not developed corresponding nanobody-based interventions. The review demonstrates how nanobody engineering advances combined with current molecular knowledge create a promising yet underdeveloped therapeutic area for cardiovascular medicine, which could use precise biologic treatments to restore vascular equilibrium and fight inflammation, thus transforming future CVD treatment approaches.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1861674","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:30:30Z","timestamp":1789482630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting vascular inflammation and endothelial dysfunction with nanobodies: emerging therapeutic strategies for cardiovascular disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Ibrahim","family":"Aljaezi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Pharmacy, Najran University","place":["Najran, Saudi Arabia"]},{"name":"Health Research Center, Najran University","place":["Najran, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1278","article-title":"World Heart Federation Roadmap for secondary prevention of cardiovascular disease: 2023 update","volume":"19","author":"Laranjo","year":"2024","journal-title":"Glob Heart"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1379785","article-title":"Genetic, lifestyle and metabolic factors contributing to cardiovascular disease in the Italian population: a literature review","volume":"11","author":"Ojeda-Granados","year":"2024","journal-title":"Front Nutr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s41182-023-00527-7","article-title":"Incidence and risk factors of cardiovascular disease among population aged 40\u201370 years: a population-based cohort study in the South of Iran","volume":"51","author":"Rezaianzadeh","year":"2023","journal-title":"Trop Med Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5455\/msm.2023.35.88-93","article-title":"Public health dimensions of CVD prevention and control - global perspectives and current situation in the Federation of BiH","volume":"35","author":"Ramic-Catak","year":"2023","journal-title":"Mater Sociomed"},{"key":"B5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4244\/eij-d-23-00606","article-title":"Targeting inflammation in atherosclerosis: overview, strategy and directions","volume":"20","author":"Waksman","year":"2024","journal-title":"EuroIntervention"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184411","article-title":"Vascular endothelial cell biology: an update","volume":"20","author":"Kr\u00fcger-Genge","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/0003319720987752","article-title":"Endothelial dysfunction and its clinical implications","volume":"72","author":"Poredos","year":"2021","journal-title":"Angiology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2906223","article-title":"Endothelial cell dysfunction: onset, progression, and consequences","volume":"29","author":"Naderi-Meshkin","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003282","article-title":"Mediterranean diet and endothelial function in patients with coronary heart disease: an analysis of the CORDIOPREV randomized controlled trial","volume":"17","author":"Yubero-Serrano","year":"2020","journal-title":"PloS Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2411306","article-title":"Advancements in the regulation of different-intensity exercise interventions on arterial endothelial function","volume":"24","author":"Li","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5551\/jat.RV22015","article-title":"Cigarette smoking and atherosclerotic cardiovascular disease","volume":"31","author":"Ishida","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Reseaarch"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-021-00625-1","article-title":"A comparative study assessing the incidence and degree of hyperkalemia in patients on angiotensin-converting enzyme inhibitors versus angiotensin-receptor blockers","volume":"36","author":"Salik","year":"2022","journal-title":"J Hum Hypertens"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55060268","article-title":"SGLT2 inhibitors: nephroprotective efficacy and side effects","volume":"55","author":"Garofalo","year":"2019","journal-title":"Med (Kaunas)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16256","article-title":"The role of platelet P2Y(12) receptors in inflammation","volume":"181","author":"Parker","year":"2024","journal-title":"Br\u00a0J Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1039\/d0nr00308e","article-title":"Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan-conjugated atorvastatin nanoparticles","volume":"12","author":"Hossaini Nasr","year":"2020"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/circresaha.119.315185","article-title":"Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation","volume":"126","author":"Boada","year":"2020"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.01.032","article-title":"Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis","volume":"29","author":"Lockhart","year":"2021","journal-title":"Mol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.7b18525","article-title":"Nitric oxide-delivering high-density lipoprotein-like nanoparticles as a biomimetic nanotherapy for vascular diseases","volume":"10","author":"Rink","year":"2018","journal-title":"ACS Appl Materials Interfaces"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvad034","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022","volume":"9","author":"Tamargo","year":"2023","journal-title":"Eur Heart J - Cardiovasc Pharmacotherapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00251-002-0433-0","article-title":"Heavy-chain antibodies in Camelidae; a case of evolutionary innovation","volume":"54","author":"Nguyen","year":"2002","journal-title":"Immunogenetics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00771","article-title":"Nanobody technology: a versatile toolkit for microscopic imaging, protein\u2013protein interaction analysis, and protein function exploration","volume":"8","author":"Beghein","year":"2017","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708536200","article-title":"Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains *","volume":"283","author":"Barthelemy","year":"2008","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.7b01221","article-title":"Comparison of three antihapten VHH selection strategies for the development of highly sensitive immunoassays for microcystins","volume":"89","author":"P\u00edrez-Schirmer","year":"2017","journal-title":"Anal Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713229","article-title":"NANOBODY(\u00ae) molecule, a giga medical tool in nanodimensions","volume":"24","author":"Kunz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: a review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/15330338211010117","article-title":"Nanobody conjugates for targeted cancer therapy and imaging","volume":"20","author":"Kang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254944","article-title":"A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics","volume":"16","author":"Lin","year":"2021","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2459795","article-title":"Quantifying antibody binding: techniques and therapeutic implications","volume":"17","author":"Lodge","year":"2025","journal-title":"MAbs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2024.2434908","article-title":"Selection of an LRP1 ligand phage-displayed single domain antibody that transmigrates the BBB","volume":"33","author":"Manrique-Su\u00e1rez","year":"2025","journal-title":"J Drug Targeting"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081131","article-title":"Transportation of single-domain antibodies through the blood-brain barrier","volume":"11","author":"Ruiz-L\u00f3pez","year":"2021","journal-title":"Biomolecules"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1042\/bst20241419","article-title":"Advances in nanobody multimerization and multispecificity: from in vivo assembly to in vitro production","volume":"53","author":"Al-Seragi","year":"2025","journal-title":"Biochem Soc Trans"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/hab-200436","article-title":"Radiomics, aptamers and nanobodies: New insights in cancer diagnostics and imaging","volume":"29","author":"Alamoudi","year":"2021","journal-title":"Hum Antibodies"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2026.201138","article-title":"Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers","volume":"34","author":"Mashayekhi","year":"2026","journal-title":"Mol Ther Oncol"},{"key":"B37","article-title":"Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide","volume":"46","author":"de Jong","year":"2005","journal-title":"J Nucl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.156729","article-title":"A novel \u00b9\u00b9\u00b9In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT\/CT imaging of prostate cancer","volume":"56","author":"Chatalic","year":"2015","journal-title":"J Nucl Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161950","article-title":"Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells","volume":"214","author":"Rashidian","year":"2017","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15515","article-title":"A guide to the generation and design of nanobodies","volume":"288","author":"Muyldermans","year":"2021","journal-title":"FEBS J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03676-z","article-title":"Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants","volume":"595","author":"Xu","year":"2021","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202100286","article-title":"Construction of synthetic nanobody library in mammalian cells by dsDNA-based strategies","volume":"22","author":"Zhao","year":"2021","journal-title":"ChemBioChem"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-animal-021419-083831","article-title":"Applications of nanobodies","volume":"9","author":"Muyldermans","year":"2021","journal-title":"Annu Rev Anim Biosci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213355","article-title":"Screening, expression, and identification of nanobody against SARS-CoV-2 spike protein","volume":"11","author":"Su","year":"2022","journal-title":"Cells"},{"key":"B46","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41598-018-37212-3","article-title":"An improved yeast surface display platform for the screening of nanobody immune libraries","volume":"9","author":"Ucha\u0144ski","year":"2019","journal-title":"Annu Rev Anim Biosci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300258120","article-title":"Structure-based design of nanobodies that inhibit seeding of Alzheimer's patient-extracted tau fibrils","volume":"120","author":"Abskharon","year":"2023","journal-title":"PNAS"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1038\/s41598-021-83198-w","article-title":"Defining the epitope of a blood-brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor","volume":"11","author":"Sheff","year":"2021","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13104-022-06001-7","article-title":"Structure-based design and construction of a synthetic phage display nanobody library","volume":"15","author":"Moreno","year":"2022","journal-title":"BMC Res Notes"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2022.2029773","article-title":"Design of nanobodies against dengue virus capsid: a computational affinity maturation approach","volume":"41","author":"Chaudhuri","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbae033","article-title":"nanoBERT: a deep learning model for gene-agnostic navigation of the nanobody mutational space","volume":"4","author":"Hadsund","year":"2024","journal-title":"Bioinf Adv"},{"key":"B52","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41598-023-27926-4","article-title":"Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation","volume":"13","author":"Poustforoosh","year":"2023","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J Biol Chem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/ac051092j","article-title":"Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing","volume":"77","author":"Saerens","year":"2005","journal-title":"Anal Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/antib8010013","article-title":"Nanobody engineering: toward next-generation immunotherapies and immunoimaging of cancer","volume":"8","author":"Chanier","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2020.02.009","article-title":"Current status of myocardial perfusion imaging with new SPECT\/CT cameras","volume":"50","author":"Piekarski","year":"2020","journal-title":"Semin Nucl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2013.11.002","article-title":"Prospects for SPECT imaging using the radiolanthanide terbium-155 \u2014 production and preclinical evaluation in tumor-bearing mice","volume":"41","author":"M\u00fcller","year":"2014","journal-title":"Nucl Med Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.2967\/jnumed.115.156729","article-title":"A novel 111 In-labeled anti\u2013prostate-specific membrane antigen nanobody for targeted SPECT\/CT imaging of prostate cancer","volume":"56","author":"Chatalic","year":"2015","journal-title":"J Nucl Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2018-0330","article-title":"Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis \u2013 impact of radiochemistry on pharmacokinetics","volume":"400","author":"Bala","year":"2019","journal-title":"400"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/srep21834","article-title":"In vivo detection of small tumour lesions by multi-pinhole SPECT applying a 99mTc-labelled nanobody targeting the epidermal growth factor receptor","volume":"6","author":"Kr\u00fcwel","year":"2016","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-014-0731-6","article-title":"Specific targeting of atherosclerotic plaques in ApoE-\/- mice using a new camelid sdAb binding the vulnerable plaque marker LOX-1","volume":"16","author":"De Vos","year":"2014","journal-title":"Mol Imaging Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1039\/c0dt01595d","article-title":"A practical guide to the construction of radiometallated bioconjugates for positron emission tomography","volume":"40","author":"Zeglis","year":"2011","journal-title":"Dalton Trans"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171306","article-title":"Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET","volume":"57","author":"Vaidyanathan","year":"2016","journal-title":"J Nucl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase I study of 68 Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"J Nucl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21532","article-title":"Near-infrared imaging of diseases: a nanocarrier approach","author":"Silindir-Gunay","year":"2019","journal-title":"Drug Dev Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-017-1134-2","article-title":"Improved debulking of peritoneal tumor implants by near-infrared fluorescent nanobody image guidance in an experimental mouse model","volume":"20","author":"Debie","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cmmi.1548","article-title":"In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies","volume":"9","author":"Bannas","year":"2014","journal-title":"Contrast Media Mol Imaging"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.03.020","article-title":"Downregulation of EGFR by a novel multivalent nanobody-liposome platform","volume":"145","author":"Oliveira","year":"2010","journal-title":"J Controlled Release"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v5.31053","article-title":"Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting","volume":"5","author":"Kooijmans","year":"2016","journal-title":"J Extracell Vesicles"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.12.007","article-title":"Nanobody-coupled microbubbles as a novel molecular tracer","volume":"158","author":"Hernot","year":"2012","journal-title":"J Controlled Release"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.12.012","article-title":"Polymeric micelles drug delivery system in oncology","volume":"159","author":"Gong","year":"2012","journal-title":"J Controlled Release"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121935","article-title":"Regulation and dysregulation of endothelial permeability during systemic inflammation","volume":"11","author":"Hellenthal","year":"2022","journal-title":"Cells"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-022-00426-z","article-title":"Design of therapeutic biomaterials to control inflammation","volume":"7","author":"Tu","year":"2022","journal-title":"Nat Rev Mater"},{"key":"B74","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2015.12.005","article-title":"Toll-like receptors mediating vascular malfunction: lessons from receptor subtypes","volume":"158","author":"Wang","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073451","article-title":"Toll-like receptors in the pathogenesis of essential hypertension. A forthcoming immune-driven theory in full effect","volume":"22","author":"Lazaridis","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004590","article-title":"PD-L1\/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way","volume":"10","author":"Yu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/CIRCRESAHA.121.318063","article-title":"Oxidative stress and hypertension","volume":"128","author":"Griendling","year":"2021","journal-title":"Circ Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1016\/j.cell.2021.06.028","article-title":"Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway","volume":"184","author":"Evavold","year":"2021","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab046","article-title":"Vascular smooth muscle cells in atherosclerosis: time for a re-assessment","volume":"117","author":"Grootaert","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010017","article-title":"The IL-1 family and its role in atherosclerosis","volume":"24","author":"Gonz\u00e1lez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00262","article-title":"Nlrp3 inflammasome and its inhibitors: a review","volume":"6","author":"Shao","year":"2015","journal-title":"Front Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S222053","article-title":"Nlrp3 inflammasome promotes diabetes-induced endothelial inflammation and atherosclerosis","volume":"12","author":"Wan","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B83","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41419-020-02985-x","article-title":"NLRP3 inflammasome in endothelial dysfunction","volume":"11","author":"Bai","year":"2020","journal-title":"Cell Death Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12951-023-02137-1","article-title":"Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury","volume":"21","author":"Van Campenhout","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.26058.1","article-title":"Interleukin-6 signalling in health and disease","volume":"9","author":"Rose-John","year":"2020","journal-title":"F1000Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.01.174","article-title":"Trans-signaling of interleukin-6 (IL-6) is mediated by the soluble IL-6 receptor, but not by soluble CD5","volume":"484","author":"Aparicio-Siegmund","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","article-title":"Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters","volume":"70","author":"Del Giudice","year":"2018","journal-title":"Brain Behavior Immun"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105343","article-title":"Bispecific soluble cytokine receptor-nanobody fusions inhibit interleukin (IL-)6 trans-signaling and IL-12\/23 or tumor necrosis factor (TNF) signaling","volume":"299","author":"Gesiorowski","year":"2023","journal-title":"J Biol Chem"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103267","article-title":"Complexity of TNF-\u03b1 signaling in heart disease","volume":"9","author":"Rolski","year":"2020","journal-title":"J Clin Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11886-018-1067-7","article-title":"Tumor necrosis factor-\u03b1 in heart failure: an updated review","volume":"20","author":"Schumacher","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"B93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/B978-0-12-803269-5.00002-4","article-title":"Chapter two - oxidative stress, inflammation, and disease","volume-title":"Oxidative Stress and Biomaterials","author":"Chatterjee","year":"2016"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.695047","article-title":"Inflammatory cytokines, immune cells, and organ interactions in heart failure","volume":"12","author":"Li","year":"2021","journal-title":"Front Physiol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11897-014-0231-7","article-title":"Targeting interleukin-1 in heart failure and inflammatory heart disease","volume":"12","author":"Van Tassell","year":"2015","journal-title":"Curr Heart Failure Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00797-1","article-title":"IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting","volume":"18","author":"Broderick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-020-01382-6","article-title":"The role of interferon-\u03b3 in cardiovascular disease: an update","volume":"69","author":"Elyasi","year":"2020","journal-title":"Inflammation Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1676988","article-title":"Atypical chemokine receptors in cardiovascular disease","volume":"119","author":"Gencer","year":"2019","journal-title":"Thromb Haemost"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411295","article-title":"Endothelin-1 in health and disease","volume":"24","author":"Banecki","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.5392","article-title":"Association of circulating monocyte chemoattractant protein\u20131 levels with cardiovascular mortality: a meta-analysis of population-based studies","volume":"6","author":"Georgakis","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30375","article-title":"The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases","volume":"236","author":"Zhu","year":"2021","journal-title":"J Cell Physiol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.2024.39.S1.1359","article-title":"The protective effects of alamandine on angiotensin II-induced cardiac dysfunction and remodeling in rats","volume":"39","author":"Md Irfan","year":"2024","journal-title":"Physiology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","article-title":"Ccl5\/ccr5 axis in human diseases and related treatments","volume":"9","author":"Zeng","year":"2022","journal-title":"Genes Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018074","article-title":"HIV protease inhibitor ritonavir impairs endothelial function via reduction in adipose mass and endothelial leptin receptor\u2010dependent increases in NADPH oxidase 1 (Nox1), C\u2010C chemokine receptor type 5 (CCR5), and inflammation","volume":"9","author":"Bruder\u2010Nascimento","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.21888","article-title":"Role of the CCL5 and its receptor, CCR5, in the genesis of aldosterone-induced hypertension, vascular dysfunction, and end-organ damage","volume":"81","author":"Costa","year":"2024","journal-title":"Hypertension"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155238","article-title":"Ginsenoside Rg1 treats ischemic stroke by regulating the CKLF1\/CCR5 axis-induced neuronal cell pyroptosis","volume":"123","author":"Long","year":"2024","journal-title":"Phytomedicine"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114859","article-title":"Ccr5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1","volume":"195","author":"Singh","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01023-z","article-title":"Targeting immune cell recruitment in atherosclerosis","volume":"21","author":"D\u00f6ring","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666180911120039","article-title":"Modified LDL particles activate inflammatory pathways in monocyte-derived macrophages: transcriptome analysis","volume":"24","author":"Orekhov","year":"2018","journal-title":"Curr Pharm Des"},{"key":"B114","doi-asserted-by":"publisher","first-page":"154385","DOI":"10.1016\/j.cyto.2018.04.028","article-title":"Il-8 negatively regulates ABCA1 expression and cholesterol efflux via upregulating miR-183 in THP-1 macrophage-derived foam cells","volume":"122","author":"Tang","year":"2019","journal-title":"Cytokine"},{"key":"B115","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10528-018-9881-6","article-title":"Association of SELP polymorphisms with soluble P-selectin levels and vascular risk in patients with type 2 diabetes mellitus: a case\u2013control study","volume":"57","author":"Kaur","year":"2019","journal-title":"Biochem Genet"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2302073","article-title":"Biomarkers of endothelial activation and dysfunction in cardiovascular diseases","volume":"23","author":"Zhang","year":"2022"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.5551\/jat.38836","article-title":"Soluble vascular cell adhesion molecules may be protective of future cardiovascular disease risk: findings from the PREVEND prospective cohort study","volume":"24","author":"Kunutsor","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051137","article-title":"MCP-1 predicts recurrent cardiovascular events in patients with persistent inflammation","volume":"10","author":"Blanco-Colio","year":"2021","journal-title":"J Clin Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121399","article-title":"The interaction affinity between vascular cell adhesion molecule-1 (VCAM-1) and very late antigen-4 (VLA-4) analyzed by quantitative FRET","volume":"10","author":"Chakraborty","year":"2015","journal-title":"PloS One"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117487","article-title":"Icam-1 and vcam-1: gatekeepers in various inflammatory and cardiovascular disorders","volume":"548","author":"Singh","year":"2023","journal-title":"Clin Chim Acta"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01878","article-title":"E-selectin ligands in the human mononuclear phagocyte system: implications for infection, inflammation, and immunotherapy","volume":"8","author":"Silva","year":"2018","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111707","article-title":"Systematic review and meta-analysis of the effect of statins on circulating E-selectin, L-selectin, and P-selectin","volume":"9","author":"Zinellu","year":"2021","journal-title":"Biomedicines"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020291","article-title":"Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications","volume":"10","author":"Kwaifa","year":"2020","journal-title":"Biomolecules"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.122.317882","article-title":"Dichotomous roles of smooth muscle cell\u2013derived MCP1 (monocyte chemoattractant protein 1) in development of atherosclerosis","volume":"42","author":"Owsiany","year":"2022","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000096","article-title":"Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies","volume":"73","author":"Xu","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.1084604","article-title":"Mitochondrial dysfunction in vascular endothelial cells and its role in atherosclerosis","volume":"13","author":"Qu","year":"2022","journal-title":"Front Physiol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102108","article-title":"Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine\/dimethylarginine dimethylaminotransferase 2 pathway","volume":"46","author":"Lee","year":"2021","journal-title":"Redox Biol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.2174\/1570180820666230613163447","article-title":"Asymmetric dimethylarginine (ADMA) in cardiovascular disease, cardiac ischemia\/reperfusion injury, and ischemic non-obstructive coronary artery disease: biochemical and pharmacological implications","volume":"21","author":"Corradi","year":"2024","journal-title":"Drug Des Discov"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15070","article-title":"Targeting microRNA-192-5p, a downstream effector of NOXs (NADPH oxidases), reverses endothelial DHFR (dihydrofolate reductase) deficiency to attenuate abdominal aortic aneurysm formation","volume":"78","author":"Huang","year":"2021","journal-title":"Hypertension"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.168245","article-title":"Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis","volume":"58","author":"Antoniades","year":"2011","journal-title":"Hypertension"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2703105","article-title":"Oxidative stress-induced endothelial dysfunction in cardiovascular diseases","volume":"27","author":"Shaito","year":"2022","journal-title":"Front Bioscience (Landmark Ed)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011010","article-title":"Neutrophil HIF-1\u03b1 stabilization is augmented by mitochondrial ROS produced via the glycerol 3-phosphate shuttle","volume":"139","author":"Willson","year":"2022","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100777","article-title":"Research progress on the molecular mechanism of coronary microvascular endothelial cell dysfunction","volume":"34","author":"Deng","year":"2021","journal-title":"Int J Cardiol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e4","article-title":"Tnf in human tuberculosis: a double-edged sword","volume":"24","author":"Yuk","year":"2024","journal-title":"Immune Netw"},{"key":"B135","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1124\/pr.118.017178","article-title":"Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products","volume":"71","author":"Wang","year":"2019","journal-title":"Pharmacol Rev"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.925923","article-title":"Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis","volume":"9","author":"Jiang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202973","article-title":"Azilsartan ameliorates ox-LDL-induced endothelial dysfunction via promoting the expression of KLF2","volume":"13","author":"Li","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S492252","article-title":"Liraglutide ameliorates renal endothelial dysfunction in diabetic rats through the inhibition of the Dll4\/Notch2 pathway","volume":"17","author":"Li","year":"2024","journal-title":"Diabetes Metab Syndrome Obesity: Targets Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2021.09.006","article-title":"Oxidized LDL, but not angiotensin II, induces cardiomyocyte hypertrophic responses through the interaction between LOX-1 and AT1 receptors","volume":"162","author":"Lin","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.310933","article-title":"Sirt3 impairment and SOD2 hyperacetylation in vascular oxidative stress and hypertension","volume":"121","author":"Dikalova","year":"2017","journal-title":"Circ Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.yjmcc.2025.06.011","article-title":"Intermedin1\u201353 improves aging-associated cardiac remodeling and dysfunction via mitochondrial SIRT3-mediated SOD2 deacetylation","volume":"205","author":"Ji","year":"2025","journal-title":"J Mol Cell Cardiol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10081238","article-title":"Angiotensin II induces oxidative stress and endothelial dysfunction in mouse ophthalmic arteries via involvement of AT1 receptors and NOX2","volume":"10","author":"Birk","year":"2021","journal-title":"Antioxidants"},{"key":"B143","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/0115701611308870240910115023","article-title":"Delineating the NOX-mediated promising therapeutic strategies for the management of various cardiovascular disorders: a comprehensive review","volume":"23","author":"Upadhyay","year":"2025","journal-title":"Curr Vasc Pharmacol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13296","article-title":"Sirt6 deficiency contributes to mitochondrial fission and oxidative damage in podocytes via the ROCK1\u2010Drp1 signalling pathway","volume":"55","author":"Chen","year":"2022","journal-title":"Cell Proliferation"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-24-544","article-title":"Role of annexin A7 in the occurrence and progression of coronary atherosclerosis: a narrative review","volume":"15","author":"Lin","year":"2025","journal-title":"Cardiovasc Diagn Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1097\/mbc.0000000000001309","article-title":"The impact of von Willebrand factor on fibrin formation and structure unveiled with type 3 von Willebrand disease plasma","volume":"35","author":"Martinez-Vargas","year":"2024","journal-title":"Blood Coagulation Fibrinolysis"},{"key":"B147","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-96-3675-4","article-title":"Vascular endothelial cells and atherosclerosis","volume-title":"Atherosclerosis: Pathology, Pathogenesis, and Clinical Significance","author":"Watanabe","year":"2025"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5620314","article-title":"The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy","volume":"2017","author":"Gragnano","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B149","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: signaling pathways and therapeutic intervention","volume":"7","author":"Kong","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009029117","article-title":"Synthetic nanobodies as angiotensin receptor blockers","volume":"117","author":"McMahon","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B151","doi-asserted-by":"publisher","first-page":"15296","DOI":"10.1038\/s41598-020-72338-3","article-title":"Endothelial dysfunction in small arteries and early signs of atherosclerosis in ApoE knockout rats","volume":"10","author":"Berenji Ardestani","year":"2020","journal-title":"Sci Rep"},{"key":"B152","doi-asserted-by":"publisher","first-page":"491","DOI":"10.14336\/ad.2021.0929","article-title":"The functional role of lipoproteins in atherosclerosis: novel directions for diagnosis and targeting therapy","volume":"13","author":"Lu","year":"2022","journal-title":"Aging Dis"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3390\/genes13050756","article-title":"Macrophage polarization in atherosclerosis","volume":"13","author":"Eshghjoo","year":"2022","journal-title":"Genes (Basel)"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.34133\/bmr.0252","article-title":"Endothelial dysfunction in atherosclerosis: experimental models and therapeutics","volume":"29","author":"Kopych","year":"2025","journal-title":"Biomater Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1381520","article-title":"Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis","volume":"11","author":"La Chica Lho\u00ebst","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.025684","article-title":"The role of efferocytosis in atherosclerosis","volume":"135","author":"Kojima","year":"2017","journal-title":"Circulation"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.845942","article-title":"Foam cells in atherosclerosis: novel insights into its origins, consequences, and molecular mechanisms","volume":"9","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1215612","article-title":"Macrophage death in atherosclerosis: potential role in calcification","volume":"14","author":"Neels","year":"2023","journal-title":"Front Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01110-1","article-title":"Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis","volume":"22","author":"Grodecki","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.112.265140","article-title":"Nanobodies targeting mouse\/human VCAM1 for the nuclear imaging of atherosclerotic lesions","volume":"110","author":"Broisat","year":"2012","journal-title":"Circ Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0989-0","article-title":"Caplacizumab: first global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs"},{"key":"B162","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac126","article-title":"Efficacy and safety of anti-TNF multivalent nanobody\u00ae compound \u2018ozoralizumab\u2019 without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Modern Rheumatol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00005-023-00685-w","article-title":"Improved production of anti-FGF-2 nanobody using Pichia pastoris and its effect on antiproliferation of keratinocytes and alleviation of psoriasis","volume":"71","author":"Zhou","year":"2023","journal-title":"Archivum Immunologiae Therapiae Experimentalis"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0000000000001185","article-title":"Nanobodies as probes and modulators of cardiovascular G protein-coupled receptors","volume":"80","author":"Wingler","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.5463\/thesis.572","article-title":"Nanobodies targeting human and viral chemokine receptors","author":"Bergkamp","year":"2024"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/art.42273","article-title":"Phase II\/III results of a trial of anti-tumor necrosis factor multivalent nanobody compound ozoralizumab in patients with rheumatoid arthritis","volume":"74","author":"Takeuchi","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac119","article-title":"Efficacy and safety of the anti-TNF multivalent nanobody\u00ae compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 52-week result of a phase II\/III study (OHZORA trial)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Modern Rheumatol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2024.12.013","article-title":"Injection of ROS-responsive hydrogel loaded with IL-1\u03b2-targeted nanobody for ameliorating myocardial infarction","volume":"46","author":"Wang","year":"2025","journal-title":"Bioact Mater"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.4c00230","article-title":"Tyrosine sulfation modulates the binding affinity of chemokine-targeting nanobodies","volume":"19","author":"Dilly","year":"2024","journal-title":"ACS Chem Biol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.07.027","article-title":"Nanobody-facilitated multiparametric PET\/MRI phenotyping of atherosclerosis","volume":"12","author":"Senders","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41467-023-36776-7","article-title":"Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody","volume":"14","author":"Nachit","year":"2023","journal-title":"Nat Commun"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.119.313088","article-title":"Ultrasound molecular imaging of atherosclerosis with nanobodies: translatable microbubble targeting murine and human VCAM (vascular cell adhesion molecule) 1","volume":"39","author":"Punjabi","year":"2019","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2023.2300694","article-title":"Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy","volume":"32","author":"Li","year":"2024","journal-title":"J Drug Targeting"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jev346","article-title":"Targeting of vascular cell adhesion molecule-1 by 18F-labelled nanobodies for PET\/CT imaging of inflamed atherosclerotic plaques","volume":"17","author":"Bala","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1022418","article-title":"Generation of high affinity ICAM-1-specific nanobodies and evaluation of their suitability for allergy treatment","volume":"13","author":"Zettl","year":"2022","journal-title":"Front Immunology Volume 13 - 2022"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-025-03994-y","article-title":"Nanobody-based Pannexin1 channel inhibitors increase survival after cardiac ischemia\/reperfusion","volume":"402","author":"Rusiecka","year":"2025","journal-title":"Cell Tissue Res"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13105-025-01108-4","article-title":"Purinergic receptors in atherosclerosis: implications for pathophysiology and therapeutic strategies","volume":"81","author":"Dabravolski","year":"2025","journal-title":"J Physiol Biochem"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV17031","article-title":"Acquired von Willebrand syndrome associated with cardiovascular diseases","volume":"26","author":"Horiuchi","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.14503\/thij-20-7402","article-title":"The cardioprotective potential of von Willebrand disease in ischemic heart disease","volume":"49","author":"Mihyawi","year":"2022","journal-title":"Tex Heart Inst J"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1153","article-title":"A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B","volume":"106","author":"Hulstein","year":"2005","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-152280","article-title":"Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients","volume":"113","author":"Federici","year":"2009","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-613935","article-title":"Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.06.014","article-title":"Molecular basis of thrombotic microangiopathy","volume":"23","author":"Zhou","year":"2025","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-017-1117-3","article-title":"Evaluation of [(99m)Tc]radiolabeled macrophage mannose receptor-specific nanobodies for targeting of atherosclerotic lesions in mice","volume":"20","author":"Bala","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3390\/bios6030034","article-title":"Enhanced biosensor platforms for detecting the atherosclerotic biomarker VCAM1 based on bioconjugation with uniformly oriented VCAM1-targeting nanobodies","volume":"6","author":"Ta","year":"2016","journal-title":"Biosens-Basel"},{"key":"B187","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molimm.2011.11.013","article-title":"Generation and characterization of a functional nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor","volume":"50","author":"Behdani","year":"2012","journal-title":"Mol Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.5b04063","article-title":"Nanobody-based electrochemical immunoassay for ultrasensitive determination of apolipoprotein-A1 using silver nanoparticles loaded nanohydroxyapatite as label","volume":"87","author":"Wang","year":"2015","journal-title":"Anal Chem"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.20964\/2017.03.32","article-title":"Electrochemical immunoassay analysis of apolipoprotein A for the potential diagnosis of coronary artery disease","volume":"12","author":"Liu","year":"2017","journal-title":"Int J Electrochem Sci"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac066.233","article-title":"Nanobodies as novel potential drugs to target cardiac light chain amyloidosis","volume":"118","author":"Broggini","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201802354R","article-title":"Targeting RyR2 with a phosphorylation site-specific nanobody reverses dysfunction of failing cardiomyocytes in rats","volume":"33","author":"Li","year":"2019","journal-title":"FASEB J"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.622473","article-title":"Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition","volume":"7","author":"Sillen","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165859","article-title":"Structural insights into the mechanism of a nanobody that stabilizes PAI-1 and modulates its activity","volume":"21","author":"Sillen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B194","first-page":"2022.2008. 2018.503988","article-title":"Cryo-EM complex structure of active GPR75 with a nanobody","volume-title":"Biorxiv","author":"Lv","year":"2022"},{"key":"B195","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1038\/s41467-022-29703-9","article-title":"Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure","volume":"13","author":"De Genst","year":"2022","journal-title":"Nat Commun"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3390\/biology14050547","article-title":"Nanobodies: from discovery to AI-driven design","volume":"14","author":"Zhu","year":"2025","journal-title":"Biol (Basel)"},{"key":"B197","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/imr.13381","article-title":"Single domain antibody: development and application in biotechnology and biopharma","volume":"328","author":"Yu","year":"2024","journal-title":"Immunol Rev"},{"key":"B198","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2015.1046648","article-title":"Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform","volume":"7","author":"Klarenbeek","year":"2015","journal-title":"MAbs"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: next generation of cancer diagnostics and therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41467-023-36106-x","article-title":"Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861674\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:30:33Z","timestamp":1789482633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861674\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":200,"alternative-id":["10.3389\/fimmu.2026.1861674"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1861674","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1861674"}}